Reintroduction of Antidepressant Therapy across Pregnancy in Women Who Previously Discontinued Treatment
Cohen L.S.a,b · Altshuler L.L.c · Stowe Z.N.d · Faraone S.V.b
A Preliminary Retrospective Study
aPerinatal and Reproductive Psychiatry Clinical Research Program, bDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Mass., cMood Disorders Research Program, Department of Psychiatry and Behavioral Medicine, University of California, Los Angeles, Calif., and dPregnancy and Postpartum Mood Disorders Program, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Ga., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: Pregnancy has frequently been described as a time of emotional well-being conferring ‘protection’ against psychiatric disorders. However, data to support this impression are sparse. Methods: A retrospective review was undertaken in order to examine rates of reintroduction of antidepressants across pregnancy among a cohort of 54 euthymic pregnant women who had discontinued these medications around the time of conception. Reintroduction of antidepressants was used as a marker suggesting relapse of depression. Results: Forty-two percent (n = 23) of these women reintroduced antidepressant therapy during pregnancy, with nearly half of these (n = 11) doing so in the first trimester. A greater time spent in episodes since depressive onset and a prior history of suicide attempts was associated with antidepressant reintroduction. Conclusions: Nearly half of the women who discontinued antidepressants during pregnancy to avoid fetal exposure appeared to experience symptoms severe enough to prompt reintroduction of treatment with these medications. The implications of these findings are discussed with respect to treatment planning for women who are maintained on antidepressants and who plan to conceive.
© 2004 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.